Bogda Koczwara1, Laura Deckx2, Shahid Ullah3, Marjan van den Akker4,5,6. 1. Department of Medical Oncology, Flinders Medical Centre and Flinders University, Adelaide, Australia. bogda.koczwara@flinders.edu.au. 2. Primary Care Clinical Unit, The University of Queensland, Brisbane, Australia. 3. College of Medicine and Public Health, Flinders University, Adelaide, Australia. 4. Institute of General Practice, Goethe University, Frankfurt, Germany. 5. Academic Center for General Practice, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium. 6. Department of Family Medicine, School CAPHRI, Maastricht University, Maastricht, The Netherlands.
Abstract
PURPOSE: To investigate if comorbidity predicts mortality and functional impairment in middle-aged individuals with cancer (50-64 years) as compared to older individuals. METHODS: A prospective cohort study. Outcomes were mortality and functional impairment at 5 years follow-up. Comorbidity was assessed using adjusted Charlson comorbidity index and polypharmacy (≥ 5 drugs) as surrogate for comorbidity. Multivariate Cox-proportional hazards and binary logit models were used to assess the risk of 5-year mortality and functional impairment respectively. RESULTS: We included 477 middle-aged (50-64 years) and 563 older (65 + years) individuals with cancer. The prevalence of comorbidity (at least one disease in addition to cancer) was 29% for middle-aged and 45% for older individuals, with polypharmacy observed in 15% and 31% respectively. Presence of ≥ 3 comorbidities was associated with nearly three times as high a risk of mortality in middle-aged individuals (HR 2.97, 95% CI: 1.43-6.16). In older individuals, the HR was 1.7 (95% CI 1.1-2.8). Polypharmacy was associated with a higher risk of mortality in middle-aged (HR 2.35, 95% CI 1.32-4.16) but not in older individuals (HR 1.2, 95% CI 0.9-1.8). Polypharmacy was associated with the four time the risk of functional impairment in middle-aged (OR 4.0, 95% CI 1.59-10.06) and older individuals (OR 4.4, 95% CI 1.6-11.7). CONCLUSION: This study of middle-aged and older adults with cancer shows that comorbid disease is common in younger and older individuals with cancer and are associated with inferior outcomes. Assessment and management of comorbidity should be a priority for cancer care across all age groups.
PURPOSE: To investigate if comorbidity predicts mortality and functional impairment in middle-aged individuals with cancer (50-64 years) as compared to older individuals. METHODS: A prospective cohort study. Outcomes were mortality and functional impairment at 5 years follow-up. Comorbidity was assessed using adjusted Charlson comorbidity index and polypharmacy (≥ 5 drugs) as surrogate for comorbidity. Multivariate Cox-proportional hazards and binary logit models were used to assess the risk of 5-year mortality and functional impairment respectively. RESULTS: We included 477 middle-aged (50-64 years) and 563 older (65 + years) individuals with cancer. The prevalence of comorbidity (at least one disease in addition to cancer) was 29% for middle-aged and 45% for older individuals, with polypharmacy observed in 15% and 31% respectively. Presence of ≥ 3 comorbidities was associated with nearly three times as high a risk of mortality in middle-aged individuals (HR 2.97, 95% CI: 1.43-6.16). In older individuals, the HR was 1.7 (95% CI 1.1-2.8). Polypharmacy was associated with a higher risk of mortality in middle-aged (HR 2.35, 95% CI 1.32-4.16) but not in older individuals (HR 1.2, 95% CI 0.9-1.8). Polypharmacy was associated with the four time the risk of functional impairment in middle-aged (OR 4.0, 95% CI 1.59-10.06) and older individuals (OR 4.4, 95% CI 1.6-11.7). CONCLUSION: This study of middle-aged and older adults with cancer shows that comorbid disease is common in younger and older individuals with cancer and are associated with inferior outcomes. Assessment and management of comorbidity should be a priority for cancer care across all age groups.
Authors: Hans Wildiers; Pieter Heeren; Martine Puts; Eva Topinkova; Maryska L G Janssen-Heijnen; Martine Extermann; Claire Falandry; Andrew Artz; Etienne Brain; Giuseppe Colloca; Johan Flamaing; Theodora Karnakis; Cindy Kenis; Riccardo A Audisio; Supriya Mohile; Lazzaro Repetto; Barbara Van Leeuwen; Koen Milisen; Arti Hurria Journal: J Clin Oncol Date: 2014-08-20 Impact factor: 44.544
Authors: Laura Deckx; Doris van Abbema; Katherine Nelissen; Liesbeth Daniels; Piet Stinissen; Paul Bulens; Loes Linsen; Jean-Luc Rummens; Geert Robaeys; Eric T de Jonge; Bert Houben; Karin Pat; Daan Walgraeve; Luc Spaas; Jolanda Verheezen; Thessa Verniest; Alexander Goegebuer; Hans Wildiers; Franchette van den Berkmortel; Vivianne C Tjan-Heijnen; Frank Buntinx; Marjan van den Akker Journal: BMC Public Health Date: 2011-10-25 Impact factor: 3.295
Authors: Peter Hanlon; Barbara I Nicholl; Bhautesh Dinesh Jani; Duncan Lee; Ross McQueenie; Frances S Mair Journal: Lancet Public Health Date: 2018-06-14
Authors: Savio G Barreto; Simone I Strasser; Geoffrey W McCaughan; Michael A Fink; Robert Jones; John McCall; Stephen Munn; Graeme A Macdonald; Peter Hodgkinson; Gary P Jeffrey; Bryon Jaques; Michael Crawford; Mark E Brooke-Smith; John W Chen Journal: Cancers (Basel) Date: 2022-06-03 Impact factor: 6.575
Authors: Dominique Schell; Shahid Ullah; Mark E Brooke-Smith; Paul Hollington; Marina Yeow; Christos S Karapetis; David I Watson; Stephen J Pandol; Claire T Roberts; Savio G Barreto Journal: Cancers (Basel) Date: 2022-01-06 Impact factor: 6.639